Medtronic has reported late-breaking data from the randomised Evolut Low Risk Trial’s five-year outcomes of the Evolut ...
At two years of follow-up, patients with a poorly functioning tricuspid valve in the heart who received the best available ...
Harrington says Valve was headhunting developers in the late 90s, and one of the ideas linked to this was to work on another ...
Velan Inc. (TSX: VLN) ("Velan" or the "Company"), a world-leading manufacturer of industrial valves, announced today the closing of the sale, by the Company's wholly-owned subsidiary, Velan Valves ...